40
Participants
Start Date
December 31, 2017
Primary Completion Date
December 31, 2019
Study Completion Date
April 30, 2020
Benralizumab
Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Collaborators (1)
AstraZeneca
INDUSTRY
Louis-Philippe Boulet
OTHER